Drug Trial Radar · NCT03625102
A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Feb 12, 2018
Primary completion
Jun 16, 2023
Study completion Jun 16, 2023
Sponsor
- Lead sponsor
- Golden Biotechnology CorporationIndustry
- Sponsor type
- Industry
- First posted
- Aug 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatitis B virus infection is a worldwide disease and is still the most common cause of hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various side-effects including renal toxicity and drug resistance or failure.
Conditions
- HBV
Interventions
AntroquinonolDrug
Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
placeboOther
The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
Primary outcomes
What the sponsor says the trial is designed to measure.
- quantitative hepatitis B surface antigen (Log qHBsAg)Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chung Shan Medical University Hospital
Taichung, Taiwan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.